Tags

Type your tag names separated by a space and hit enter

Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study).
Alcohol Alcohol. 1998 Nov-Dec; 33(6):631-8.AA

Abstract

A three-armed, randomized, multicentre, placebo-controlled double-blind study was used to examine the efficacy of benfotiamine vs a combination containing benfotiamine and vitamins B6 and B12 in out-patients with severe symptoms of alcoholic polyneuropathy (Benfotiamine in treatment of Alcoholic Polyneuropathy, BAP I). The study period was 8 weeks and 84 patients fulfilled all the prerequisite criteria and completed the study as planned. Benfotiamine led to significant improvement of alcoholic polyneuropathy. Vibration perception (measured at the tip of the great toe) significantly improved in the course of the study, as did motor function. and the overall score reflecting the entire range of symptoms of alcoholic polyneuropathy. A tendency toward improvement was evident for pain and co-ordination; no therapy-specific adverse effects were seen.

Authors+Show Affiliations

Psychiatrisches Krankenhaus, Giessen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

9872352

Citation

Woelk, H, et al. "Benfotiamine in Treatment of Alcoholic Polyneuropathy: an 8-week Randomized Controlled Study (BAP I Study)." Alcohol and Alcoholism (Oxford, Oxfordshire), vol. 33, no. 6, 1998, pp. 631-8.
Woelk H, Lehrl S, Bitsch R, et al. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). Alcohol Alcohol. 1998;33(6):631-8.
Woelk, H., Lehrl, S., Bitsch, R., & Köpcke, W. (1998). Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). Alcohol and Alcoholism (Oxford, Oxfordshire), 33(6), 631-8.
Woelk H, et al. Benfotiamine in Treatment of Alcoholic Polyneuropathy: an 8-week Randomized Controlled Study (BAP I Study). Alcohol Alcohol. 1998 Nov-Dec;33(6):631-8. PubMed PMID: 9872352.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). AU - Woelk,H, AU - Lehrl,S, AU - Bitsch,R, AU - Köpcke,W, PY - 1999/1/1/pubmed PY - 1999/1/1/medline PY - 1999/1/1/entrez SP - 631 EP - 8 JF - Alcohol and alcoholism (Oxford, Oxfordshire) JO - Alcohol Alcohol VL - 33 IS - 6 N2 - A three-armed, randomized, multicentre, placebo-controlled double-blind study was used to examine the efficacy of benfotiamine vs a combination containing benfotiamine and vitamins B6 and B12 in out-patients with severe symptoms of alcoholic polyneuropathy (Benfotiamine in treatment of Alcoholic Polyneuropathy, BAP I). The study period was 8 weeks and 84 patients fulfilled all the prerequisite criteria and completed the study as planned. Benfotiamine led to significant improvement of alcoholic polyneuropathy. Vibration perception (measured at the tip of the great toe) significantly improved in the course of the study, as did motor function. and the overall score reflecting the entire range of symptoms of alcoholic polyneuropathy. A tendency toward improvement was evident for pain and co-ordination; no therapy-specific adverse effects were seen. SN - 0735-0414 UR - https://www.unboundmedicine.com/medline/citation/9872352/Benfotiamine_in_treatment_of_alcoholic_polyneuropathy:_an_8_week_randomized_controlled_study__BAP_I_Study__ L2 - https://academic.oup.com/alcalc/article-lookup/doi/10.1093/alcalc/33.6.631 DB - PRIME DP - Unbound Medicine ER -